<DOC>
	<DOCNO>NCT00231790</DOCNO>
	<brief_summary>Overactive bladder prevalent postmenopausal woman . The current study design investigate whether new drug may offer safe effective treatment .</brief_summary>
	<brief_title>A Placebo-Controlled Study MK0634 Patients With Overactive Bladder ( 0634-007 )</brief_title>
	<detailed_description>Clinical development MK-0634 discontinued . Study MK-0634-027 safety follow-up study determine ocular effect MK-0634 participant United Kingdom expose MK-0634 007 study .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Postmenopausal female ( age 4074 ) predominantly urge urinary incontinence overactive bladder episode . Patients must meet minimum eligibility requirement ( e.g. , average number micturitions/day ) base screen diary card . Patients must suffer diabetes insipidus Hyperglycemia Hypercalcemia Orthostatic hypotension Active/recurrent urinary tract infection ( &gt; 6 episode per year ) Patients must willing discontinue current OAB medication therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>